Nomination Committee appointed at Iconovo AB
At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the…
Iconovo announces that the terms and conditions for allotment of shares in directed issue are met
The Board of Directors of Iconovo AB ("Iconovo" or the "Company") resolved on 25 November 2025 on a directed share issue of approximately SEK 25 million (the "Directed Issue"), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company's existing shareholders (the "Rights Issue", together the "Issues"). The Issues were approved by the Extraordinary General Meeting in the Company on 15 December 2025. The Board of Directors has today resolved to postpone subscription and payment in the Directed Issue.
Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments
The Board of Directors of Iconovo AB ("Iconovo" or the "Company") has today resolved on a directed share issue of approximately SEK 25 million (the "Directed Issue"), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company's existing shareholders (the "Rights Issue", together the "Issues"). The Directed Issue is directed to the Company's existing principal owners Färna Invest AB ("Färna Invest") and FSG Fund II AB ("FSG"). The subscription price per share in the Issues amounts to SEK 1.15. The main purpose of the Issues is to ensure continued operation in the Company for at least 12 months, with undiminished progress in existing projects that are now subject to active out-licensing. The Issues are subject to approval by the Extraordinary General Meeting on 15 December 2025. The Rights Issue is covered to 100 percent by subscription undertakings and guarantee commitments from the Company's board members and existing shareholders. Notice of the Extraordinary General Meeting will be published through a separate press release. Due to the Rights Issue, the Board of Directors has decided to bring forward the publication of the year-end report for 2025 to 12 February 2026.
Iconovo appoints new CEO
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board of Directors has in parallel initiated a process to recruit a permanent CEO, for which Anders also is a candidate.
QUARTERLY REPORT Q3 2025
SIGNIFICANT EVENTS DURING 1 JULY – 30 SEPTEMBER 2025During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term…
Iconovo reworks its strategic goals
Iconovo AB (publ), a leading company in the development of inhalable medicines based on proprietary inhalers and dry powder formulations, today announces that it is leaving the financial targets communicated on June 1, 2022. The goals are under revision and will focus on optimizing the value and commercialization of the company's fully developed inhalers, as well as the development of an intranasal version of the best-selling GLP-1 analogue semaglutide. The purpose of the recent organizational change was to further strengthen this direction.
Iconovo AB changes Certified Adviser to Tapper Partners AB
Iconovo AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.
QUARTERLY REPORT Q2 2025
SIGNIFICANT EVENTS DURING 1 APRIL – 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately…
Iconovo’s rights issue is registered – conversion of BTA into shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG,…
Iconovo’s development of intranasal GLP-1 for a more convenient treatment of obesity is making significant progress
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announce that the development of spray-dried formulations of intranasal GLP-1 is making significant progress. Iconovo has obtained several batches of formulations from its partner Lonza and begun feasibility studies in ICOone Nasal®. Data shows impressive and consistent capabilities suitable for nasal inhalation.
